Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins

Clélia Mathieu; Samir Messaoudi; Elias Fattal; Juliette Vergnaud-Gauduchon

doi:10.20517/cdr.2019.26

Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins

Clélia Mathieu
, Samir Messaoudi
, Elias Fattal
, Juliette Vergnaud-Gauduchon

Université Paris-Sud
Université Paris-Sud

Résultats de recherche: Contribution à un journal › Article de révision › Revue par des pairs

Résumé

Nanocarriers have been developed in order to protect drugs or to improve drugs efficiency by reaching the damaged tissue and avoiding systemic and local toxicity. By using HSP90 inhibitors, some cancer drug resistances have been overcome and the loading into nanocarriers of such drugs has shown an increase of their activities. This review will present some advantages of HSP90 inhibitors to treat resistant tumors; especially those targeting the mitochondrial protein TRAP1. We will also focus on the targeting of the primary tumors, cancer stem cells and metastatic cells.

langue originale	Anglais
Pages (de - à)	381-398
Nombre de pages	18
journal	Cancer Drug Resistance
Volume	2
Numéro de publication	3
Les DOIs	https://doi.org/10.20517/cdr.2019.26
état	Publié - 1 janv. 2019
Modification externe	Oui

SDG des Nations Unies

Ce résultat contribue à ou aux Objectifs de développement durable suivants

SDG 3 Bonne santé et bien-être

Accès au document

10.20517/cdr.2019.26

Contient cette citation

@article{bd71d1d73e3c4bf38cf772b8134715ce,

title = "Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins",

abstract = "Nanocarriers have been developed in order to protect drugs or to improve drugs efficiency by reaching the damaged tissue and avoiding systemic and local toxicity. By using HSP90 inhibitors, some cancer drug resistances have been overcome and the loading into nanocarriers of such drugs has shown an increase of their activities. This review will present some advantages of HSP90 inhibitors to treat resistant tumors; especially those targeting the mitochondrial protein TRAP1. We will also focus on the targeting of the primary tumors, cancer stem cells and metastatic cells.",

keywords = "Cancer, Heat-shock proteins, Nanoparticles, Resistance",

author = "Cl{\'e}lia Mathieu and Samir Messaoudi and Elias Fattal and Juliette Vergnaud-Gauduchon",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2019.",

year = "2019",

month = jan,

day = "1",

doi = "10.20517/cdr.2019.26",

language = "English",

volume = "2",

pages = "381--398",

journal = "Cancer Drug Resistance",

issn = "2578-532X",

publisher = "OAE Publishing Inc.",

number = "3",

}

TY - JOUR

T1 - Cancer drug resistance

T2 - rationale for drug delivery systems and targeted inhibition of HSP90 family proteins

AU - Mathieu, Clélia

AU - Messaoudi, Samir

AU - Fattal, Elias

AU - Vergnaud-Gauduchon, Juliette

N1 - Publisher Copyright: © The Author(s) 2019.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Nanocarriers have been developed in order to protect drugs or to improve drugs efficiency by reaching the damaged tissue and avoiding systemic and local toxicity. By using HSP90 inhibitors, some cancer drug resistances have been overcome and the loading into nanocarriers of such drugs has shown an increase of their activities. This review will present some advantages of HSP90 inhibitors to treat resistant tumors; especially those targeting the mitochondrial protein TRAP1. We will also focus on the targeting of the primary tumors, cancer stem cells and metastatic cells.

AB - Nanocarriers have been developed in order to protect drugs or to improve drugs efficiency by reaching the damaged tissue and avoiding systemic and local toxicity. By using HSP90 inhibitors, some cancer drug resistances have been overcome and the loading into nanocarriers of such drugs has shown an increase of their activities. This review will present some advantages of HSP90 inhibitors to treat resistant tumors; especially those targeting the mitochondrial protein TRAP1. We will also focus on the targeting of the primary tumors, cancer stem cells and metastatic cells.

KW - Cancer

KW - Heat-shock proteins

KW - Nanoparticles

KW - Resistance

U2 - 10.20517/cdr.2019.26

DO - 10.20517/cdr.2019.26

M3 - Review article

AN - SCOPUS:85098761268

SN - 2578-532X

VL - 2

SP - 381

EP - 398

JO - Cancer Drug Resistance

JF - Cancer Drug Resistance

IS - 3

ER -

Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins

Résumé

SDG des Nations Unies

Accès au document

Empreinte digitale

Contient cette citation